Clinical Trials
11 trialsNCT03292133 2025-06-10
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT01610336 2021-04-08
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Novartis
Phase 2 Completed
NCT01466660 2020-04-07
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Boehringer Ingelheim
Phase 2 Completed
NCT02179671 2019-08-02
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
AstraZeneca
Phase 2 Completed
NCT00357734 2016-08-30
Iressa Follow-up Trial
AstraZeneca
Phase 3 Completed
NCT01530334 2016-02-23
ICARUS
AstraZeneca
Phase 2 Completed
NCT00588445 2016-01-22
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00096486 2016-01-21
Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00104728 2012-10-31
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
NCT00344773 2010-06-29
First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
AstraZeneca
Phase 2 Completed
NCT00264498 2009-08-03
Phase II Iressa & Carbo/Gem in NSCLC
AstraZeneca
Phase 2 Completed